bit.bio secured $25 million in Series D funding to scale its human cell models, aiming for broader industry-standard adoption as drug discovery demand rises. The company said the capital will support scaling and operational growth tied to the use of human cell systems in preclinical and translational workflows. The round signals continued investor appetite for tools that can help drug developers move from discovery into reliable model-based decision-making. For the sector, the focus on human cell models mirrors a wider shift toward platform-like capabilities that reduce dependence on animal systems and shorten translational uncertainty.